Yamazaki, Ryuichi
Matsuda, Yuki
Oba, Mari
Oi, Hideki
Kito, Shinsuke
Funding for this research was provided by:
Teijin Pharma
National Center of Neurology and Psychiatry
Article History
Received: 9 July 2022
Accepted: 8 June 2023
First Online: 16 June 2023
Declarations
:
: The study has been approved by the National Center of Neurology and Psychiatry Clinical Research Review Board (approval number: CR21-004). All the participants will provide written informed consent and will be informed of their right to withdraw from the study before participation.
: Not applicable.
: Ryuichi Yamazaki reports personal fees from Inter-Riha CO., Ltd., outside the submitted work; Shinsuke Kito reports grants and personal fees from Inter Reha CO., Ltd., Kyowa Pharmaceutical Industry CO., Ltd., Sumitomo Pharma CO., Ltd., Otsuka Pharmaceutical CO., Ltd., Teijin Pharma Limited, and Viatris Inc., outside the submitted work; Mari Oba received personal fees from Astrazeneca K.K., EP-SOGO Co., Ltd., and Pfizer Inc., outside the submitted work; Hideki Oi received research funding from Otsuka Pharmaceutical CO., Ltd., Sumitomo Pharma Co., Ltd.; the other authors have no competing interests to disclose.